GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » Total Stockholders Equity

Acotec Scientific Holdings (HKSE:06669) Total Stockholders Equity : HK$1,418.1 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings Total Stockholders Equity?

Acotec Scientific Holdings's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$1,418.1 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Acotec Scientific Holdings's Book Value per Share for the quarter that ended in Dec. 2023 was HK$4.53. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Acotec Scientific Holdings's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.18.

Acotec Scientific Holdings Total Stockholders Equity Historical Data

The historical data trend for Acotec Scientific Holdings's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings Total Stockholders Equity Chart

Acotec Scientific Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
41.19 -333.12 1,478.17 1,425.03 1,418.12

Acotec Scientific Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only 1,478.17 1,436.31 1,425.03 1,427.65 1,418.12

Acotec Scientific Holdings  (HKSE:06669) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Acotec Scientific Holdings's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1418.115-0)/313.389
=4.53

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Acotec Scientific Holdings's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(39.308 + 216.633) / 1418.115
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acotec Scientific Holdings Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Acotec Scientific Holdings (HKSE:06669) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » Total Stockholders Equity
Comparable Companies
HKSE:01763 HKSE:02190 HKSE:02160 HKSE:06922 HKSE:09996 HKSE:01696 HKSE:02500 HKSE:02235 HKSE:02407 HKSE:06118 ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
7W3:Germany
Address
16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN
Website
http://www.acotec.cn
Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.
Executives
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Nexus Partners Group Limited 2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited 2101 Beneficial owner
Li Jing 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p. 2201 Interest of corporation controlled by you
Cpe Funds Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited 2101 Beneficial owner
Cpe Holdings Limited 2201 Interest of corporation controlled by you
Cpe Holdings International Limited 2201 Interest of corporation controlled by you
Cpe Gof Gp Limited 2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p. 2201 Interest of corporation controlled by you
Boston Scientific Corporation 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings (HKSE:06669) Headlines

No Headlines